PT  - JOURNAL ARTICLE
AU  - Robert E. Sobol
AU  - Kerstin B. Menander
AU  - Sunil Chada
AU  - Dora Wiederhold
AU  - Beatha Sellman
AU  - Max Talbott
AU  - John J. Nemunaitis
TI  - Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
AID  - 10.1101/2021.01.06.20248743
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.06.20248743
4099  - http://medrxiv.org/content/early/2021/01/06/2021.01.06.20248743.short
4100  - http://medrxiv.org/content/early/2021/01/06/2021.01.06.20248743.full
AB  - Background We conducted a meta-analysis of previous adenoviral p53 (Ad-p53) treatment data in recurrent head and neck squamous cell carcinoma (HNSCC) patients to identify optimal Ad-p53 treatment methods for future clinical trials.Methods The meta-analysis involved recurrent HNSCC patients treated with Ad-p53 for whom p53 genotyping and immunohistochemistry tumor biomarker studies had been performed (n = 70). Ad-p53 tumor treatment responses defined by RECIST 1.1 criteria were correlated with Ad-p53 dose and tumor p53 biomarkers. Gene expression profiles induced by Ad-p53 treatment were evaluated using the Nanostring IO 360 panel.Results Ad-p53 dose based upon the injected tumor volume had a critical effect on tumor responses. All responders had received Ad-p53 doses greater than 7 × 1010 viral particles/cm3 of tumor volume. There was a statistically significant difference in tumor responses between patients treated with greater than 7 × 1010 viral particles/cm3 compared to patients treated at lower Ad-p53 doses (Tumor Response 31% (9/29) for Ad-p53 > 7 × 1010 viral particles/cm3 versus 0% (0/25) for Ad-p53 < 7 × 1010 viral particles/cm3; p = 0.0023). All responders were found to have favorable p53 biomarker profiles defined by less than 20% p53 positive tumor cells by immunohistochemistry (IHC), wild type p53 gene sequence or p53 deletions, truncations, or frame-shift mutations without functional p53 tetramerization domains. Preliminary gene expression profiling results revealed that Ad-p53 treatment increased Type I Interferon signaling, decreased TGF-beta and beta-catenin signaling resulting in an increased CD8+ T cell signature which are associated with increased responses to immune checkpoint blockade.Conclusions Our findings have important implications for future p53 targeted cancer treatments and identify fundamental principles to guide Ad-p53 gene therapy. We discovered that previous Ad-p53 clinical trials were negatively impacted by the inclusion of patients with unfavorable p53 biomarker profiles and by under dosing of Ad-p53 treatment. Future Ad-p53 clinical trials should have favorable p53 biomarker profiles inclusion criteria and Ad-p53 dosing above 7 × 1010 viral particles/cm3 of injected tumor volume. Preliminary gene expression profiling identified p53 mechanisms of action associated with responses to immune checkpoint blockade supporting evaluation of Ad-p53 in combination with immune checkpoint inhibitors.Competing Interest StatementThis work was supported by MultiVir Inc. Conflict of Interest RES, SC, KBM, MT, BS and DW had consulting relationships with MultiVir Inc. The remaining authors have no conflicts of interest to declare. Clinical TrialNCT03544723Funding StatementThis work was supported by MultiVir Inc. Conflict of Interest RES, SC, KBM, MT, BS and DW had consulting relationships with MultiVir Inc. The remaining authors have no conflicts of interest to declare. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies involving human participants were reviewed and approved by the ethics committee of the University of Toledo and other clinical trial centers where the patients were treated. The patients/participants provided their written informed consent to participate in the clinical trials analyzed in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the conclusions of this article are either incorporated in the manuscript, its supplemental section or available by the corresponding author upon reasonable request.